Saruparib

• A trial to learn how safe AZD9750 is and how well it works in people with metastatic prostate cancer when given with or without other antica… Pending
  2024-516976-14-00 Phase I (FiH) 2 countries AstraZeneca AB
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 Phase III 11 countries AstraZeneca AB
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting
  2024-513586-39-00 Phase III 11 countries AstraZeneca AB
• A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting
  2023-504180-16-00 Phase III 10 countries AstraZeneca AB
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Ended
  2023-508536-64-00 Phase I/II 1 country AstraZeneca AB
• Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended
  2022-502856-29-00 Phase I (FiH) 5 countries AstraZeneca AB
• A trial to learn how safe saruparib is and how well it works in people with advanced ovarian cancer Ended
  2024-519044-32-00 Phase I/II 2 countries AstraZeneca AB
• Trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer Ended
  2024-516558-24-00 Phase II 1 country Centre Leon Berard

Showing 1–8 of 8 trials